Dabigatran Versus Warfarin With NVAF Who Undergo PCI
Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This study is to compare the efficacy and safety of dabigatran ethidium b.i.d.+ clopidogrel +
ASA [100 mg q.d. *1 month] and warfarin + clopidogrel + ASA [100 mg, q.d.*1 month] in Chinese
NVAF patients undergoing PCI with stenting (elective or due to ACS).
Phase:
Phase 4
Details
Lead Sponsor:
Shenyang Northern Hospital
Collaborators:
Beijing Anzhen Hospital Second Affiliated Hospital of Third Military Medical University